Management of malignant pleural mesothelioma: A critical review

Current Opinion in Pulmonary Medicine

Volumn 6, Issue 4, 2000, Pages 267-274

  Lee, Y C Gary ^a   Light, Richard W ^a   Musk, A William ^b  

^a SAINT THOMAS HOSPITAL   (United States)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; METHOTREXATE; PLATINUM; VINBLASTINE; VINCA ALKALOID; VINCRISTINE;

CANCER IMMUNOTHERAPY; CANCER SURVIVAL; HUMAN; LUNG RESECTION; MULTIMODALITY CANCER THERAPY; PALLIATIVE THERAPY; PLEURA MESOTHELIOMA; QUALITY OF LIFE; REVIEW;

EID: 0033930538     PISSN: 10705287     EISSN: None     Source Type: Journal    
DOI: 10.1097/00063198-200007000-00003     Document Type: Review

References (83)

1. 1 Peto J, Hodgson JT, Matthews FE, Jones JR: Continuing increase in mesothelioma mortality in Britain. Lancet 1995, 345:535-539.
2. 2 Sterman DH, Kaiser LR, Albelda SM: Gene therapy for malignant pleural mesothelioma. Hematol Oncol Clin North Am 1998, 12(3):553-568.
3. 3 Armstrong BK, Musk AW, Baker JE, et al.: Epidemiology of malignant mesothelioma in Western Australia. Med J Aust 1984, 141(2):86-88.
4. 4 Peto J, Decarli A, La Vecchia C, et al.: The European mesothelioma epidemic. Br J Cancer 1999, 79:666-672.
5. 5 Pisani RJ, Colby TV, Williams DE: Malignant mesothelioma of the pleura. Mayo Clin Proc 1988, 63:1234-1244.
6. 6 Sterman DH, Kaiser LR, Albelda SM: Advances in the treatment of malignant pleural mesothelioma. Chest 1999, 116:504-520. This is an excellent review on the recent advances in treatment of mesothelioma, with emphasis on emerging modalities.
7. 7 Vallieres E: The Grondin/Sugarbaker article reviewed [comments]. Oncology 1999, 13(7):926.
8. 8 Astoul P: Pleural mesothelioma. Curr Opin Pulm Med 1999, 5:259-268.
9. 9 Hulks G, Thomas JSJ, Waclawski E: Malignant pleural mesothelioma in western Glasgow 1980-1986. Thorax 1989, 44:496-500.
10. 10 King JAC, Rucker JA, Wong SW: Mesothlioma: a study of 22 cases. South Med J 1997, 90(2):199-205.
11. 11 Baldini EH, Recht A, Strauss GM, et al.: Patterns of failure after trimodality therapy for malignant pleural mesothelioma. Ann Thorac Surg 1997, 63(2):334-338.
12. 12 Lanphear BP, Buncher CR: Latent period for malignant mesothelioma of occupational origin. J Occup Med 1992, 34:718-721.
13. 13 Antman KH: Malignant mesothelioma. N Engl J Med 1980:200-202.
14. 14 Aisner J: Current approach to malignant mesothelioma of the pleura. Chest 1995, 107(6):332S-344S.
15. 15 Law MR, Gregor A, Hodson ME, et al.: Malignant mesothelioma of the pleura: a study of 52 treated and 64 untreated patients. Thorax 1984, 39:255-259.
16. 16 Pass HI, Pogrebniak HW: Malignant pleural mesothelioma. Curr Probl Surg 1993, 30(10):921-1012.
17. 17 Light RW: Malignant pleural effusions. In: Pleural Diseases, 3rd ed. Edited by Light RW. Baltimore: Williams & Wilkins, 1995:94-116.
18. 18 Putnam JB, Light RW, Rodriguez RM, et al.: A randomized comparison of indwelling pleural catheter and doxycycline pleurodesis in the management of malignant pleural effusions. Cancer 1999, 86:1992-1999.
19. 19 Bryne MJ, Davidson JA, Musk AW, et al: Cisplatin and gemcitabine treatment for malignant mesothelioma: a phase II study. J Clin Oncol 1999, 17(1):25-30. This study, using a new combination chemotherapy regimen, demonstrates a response rate of 48%. The paper reports symptomatic benefit in responders, raising the possibility that chemotherapy may be useful for symptom palliation.
20. 20 Middleton GW, Smith IE, O'Brien MER, et al.: Good symptom relief with palliative MVP (mitomycin C, vinblastine, cisplatin) chemotherapy in malignant mesothelioma. Ann Oncol 1998, 9:269-273.
21. 21 Worn H: Möglichkeiten und Ergebnisse der chirurgischen Behandlung des malignen Pleuramesothelioms. Thorax-Chirurgie 1974, 22:391-393.
22. 22 Rusch VW, Piantadosi S, Homes EC: The role of extrapleural pneumonectomy in malignant pleural mesothelioma. A Lung Cancer Study Group trial, J Thorac Cardiovasc Surg 1991, 102:1-9.
23. 23 Rusch VW: Indications for pneumonectomy: extrapleural pneumonectomy. Chest Surg Clin North Am 1999, 9(2):327-338.
24. 24 Sugarbaker DJ, Jaklittsch MT, Liptay MJ: Mesothelioma and radical multimodality therapy: who benefits? Chest 1995, 107:345S-350S.
25. 25 Boutin C, Schlesser M, Frenay C, Astoul P: Malignant pleural mesothelioma. Eur Respir J 1998, 12:972-981.
26. 26 Sugarbaker DJ, Richards WG, Garcia JP: Extrapleural pneumonectomy for malignant mesothelioma. Adv Surg 1998, 31:252-270.
27. 27 Ryan CW, Herndon J, Vogelzand NJ: A review of chemotherapy trials for malignant mesothelioma. Chest 1998, 113:66S-73S.
28. 28 Ong ST, Vogelzang NJ: Chemotherapy in malignant pleural mesothelioma: a review. J Clin Oncol 1996, 14:1007-1017.
29. 29 Baas P, Schouwink H, Zoetmulder FAN: Malignant pleural mesothelioma. Ann Oncol 1998,9:139-149.
30. 30 Krarup-Hansen A, Hansen HH: Chemotherapy in malignant mesothelioma: a review. Cancer Chemother Pharmacol 1991, 28:319-330.
31. 31 Tammilehto I, Maasilta P, Mantyla M, et al.: Oral etoposide in the treatment of malignant mesothelioma: a phase II study. Ann Oncol 1994, 5:949-950.
32. 32 Cowan JD, Green S, Lucas J, et al.: Phase II trial of 5 day intravenous infusion of vinblastine sulfate in patients with diffuse malignant mesothelioma: a Southwest Oncology Group study [letter]. Invest New Drugs 1988, 6:247-248.
33. 33 Martensson G, Sorenson S: A phase II study of vincristine in malignant mesothelioma: a negative report. Cancer Chemother Pharmacol 1989, 24:133-134.
34. 34 Solheim OP, Saeter G, Flnnanger AM, et al.: High-dose methotrexate in the treatment of malignant mesothelioma of the pleura: a phase II study. Br J Cancer 1 992, 65:956-960.
35. 35 Breau JL, Boaziz C, Morere JJF, et al.: Combination chemotherapy with cisplatinum, adriamycin, bleomycin and mitomycin C, plus systemic and intra-pleural hyaluronidase in 25 consecutive cases of stages II, III pleural mesothelioma. Proc First Int Mesothelioma Conf, Paris, France 1991:5.
36. 36 Casper ES, Kelson DP, Alcock NW, et al.: IP cisplatin in patients with malignant ascites: Pharmacokinetic evaluation and comparison with the IV route. Cancer Treatment Reports 1985, 67:236-238.
37. 37 Markman M, Cleary S, Pfeifle C, et al.: Cisplatin administered by the intracavitary route as treatment for malignant mesothelioma. Cancer 1986, 58:18-21.
38. 38 Hakkinen AM, Lassonen A, Linnainmaa K, Mattson K, Pyrhonon S: Radiosensitivity of mesothelioma cell lines. Acta Oncol 1996, 35:451-456.
39. 39 Moskal TL, Urschel JD, Anderson TM, Antkowiak JG, Takita H: Malignant pleural mesothelioma. Surg Oncol 1999, 7:5-12. This review provides a useful table comparing the results of different multimodality therapies.
40. 40 Gordon W, Antman KH, Greenberger JS, Weichselbaum RR, Chaffely JT: Radiation therapy in the management of patients with mesothelioma. Int J Radiation Oncol 1982, 8:19-25.
41. 41 Alberts AS, Falkson G, Goedhafs L, et al.: Malignant pleural mesothelioma: a disease unaffected by current therapeutic maneuvers. J Clin Oncol 1988, 6(3):527-535.
42. 42 Brady LW: Mesothelioma, the role for radiation therapy. Semin Oncol 1981, 8:329-334.
43. 43 Boutin C, Roy F, Viallat JR, et al.: Prevention of malignant seeding after invasive diagnostic procedures in patients with pleural mesothelioma. Chest 1996, 108:754-758.
44. 44 Lee YC, Musk AW, Dean A, Thompson RI, Robinson BWS: Clinical Aspects of Mesothelioma. In: Mesothelioma. Edited by Robinson BWS, Chahinian P. Chur, Switzerland: Harwood Academic Press, in press.
45. 45 Albelda SM: Gene Therapy for lung cancer and mesothelioma. Chest 1997, 111:144S-149S.
46. 46 Schwarzenberger P, Harrison L, Weinacker A, et al.: Gene therapy for malignant mesothelioma: a novel approach for an incurable cancer with increased incidence in Louisiana. J La State Med Soc 1998, 150:168-174.
47. 47 Goey SH, Eggermont AM, Punt CJ, et al.: Intrapleural administration of interleukin 2 in pleural mesothelioma: a phase I-II study. Br J Cancer 1995, 72:1283-1288.
48. 48 Yasumoto K, Mivazaki K, Nagashima A, et al.: Induction of lymphokine-activated killer cells by intrapleural instillations of recombinant interleukin-2 in patients with malignant pleurisy due to cancer. Cancer Res 1987, 47:2184-2187.
49. 49 Robinson BWS: Asbestos and cancer: human natural killer cell activity is suppressed by asbestos fibers but restored by rlL-2. Am J Respir Dis 1989, 139:897-901.
50. 50 Manning LS, Bowman RV, Darby SB, Robinson BW: Lysis of human malignant mesothelioma cells by natural killer and lymphokine-activated killer cells. Am Rev Respir Dis 1989, 139:1369-1374.
51. 51 Astoul P, Bertault-Peres P, Durand A, Catalin J, Vignal F, Boutin C: Pharmacokinetics of intrapleural recombinant interleukin 2 in immunotherapy for malignant pleural effusion. Cancer 1994, 73:308-313.
52. 52 Astoul P, Picat-Joossen D, Viallat JR, et al: Intrapteural administration of interleukin-2 for the treatment of patients with malignant pleural mesothelioma: a phase II study. Cancer 1998, 83:2099-2104.
53. 53 Boutin C, Nussbaum E, Monnet I, et al.: Intrapleural treatment with recombinant gamma-interferon in early stage malignant pleural mesothelioma. Cancer 1994, 74:2460-2467.
54. 54 Upham JW, Musk AW, Van-Hagel G, et al.: Interferon alpha and doxorubicin in malignant mesothelioma: a phase II study. Aust NZ J Med 1993, 23:683-687.
55. 55 Soulie P, Ruffie P, Trandafir L, et al.: Combined systemic chemoimmunotherapy in advanced diffuse malignant mesothelioma: report of a phase I-II study of weekly cisplatin/interferon alfa-2a. J Clin Oncol 1996, 14:878-885.
56. 56 Trandafir L, Ruffie P, Borel C, et al.: Higher doses of alpha-interferon do not increase the activity of the weekly cisplatin-interferon combination in advanced malignant mesothelioma. Eur J Cancer 1997, 33(11):1900-1902.
57. 57 O'Reilly EM, Ilson DH, Saltz LB, et al.: A phase II trial of interferon alpha 2-a and carboplatin in patients with advanced malignant mesothelioma. Cancer Invest 1999, 17:195-200.
58. 58 Pass HI, Temeck BK, Kranda K, et al.: A phase II trial investigating primary immunotherapy for malignant pleural mesothelioma and the feasibility of adjuvant immunochemotherapy after maximal cytoreduction. Ann Surg Oncol 1995, 2:214-220.
59. 59 Von Hoff DD, Metch B, Lucas JG, et al.: Phase II evaluation of recombinant interferon-beta in patients with diffuse mesothelioma: a Southwest Oncology Group study. J Interferon Res 1990, 10:531-534.
60. 60 Rice TW, Adelstein DJ, Kirby TJ, et al.: Aggressive multimodality therapy for malignant pleural mesothelioma. Ann Thorac Surg 1994, 58:24-29.
61. 61 Sauter ER, Langer C, Coia LR, et al.: Optimal management of malignant mesothelioma after subtotal pleurectomy: revisiting the role of intrapleural chemotherapy and postoperative radiation. J Surg Oncol 1995, 60:100-105.
62. 62 Lee JD, Ferez S, Wang HJ, et al.: Intrapleural chemotherapy for patients with incompletely resected malignant mesothelioma: the UCLA experience. J Surg Oncol 1995, 60:262-267.
63. 63 Pass HI, Temeck BK, Kranda K, et al: Phase III randomized trial of surgery with or without intraoperative photodynamic therapy and postoperative immunochemotherapy for malignant pleural mesothelioma. Ann Surg Oncol 1997,4:628-633.
64. 64 Takita H, Dougherty TJ: Intracavitary photodynamic therapy for malignant pleural mesothelioma. Semin Oncol 1995, 11:368-371.
65. 65 Hilaris BS, Nori D, Kwong E, Kutcher GJ, Marini N: Pleurectomy and intraoperative brachytherapy and postoperative radiation in the treatment of malignant pleural mesothelioma. Int J Radiation Oncol 1984, 10:325-331.
66. 66 Sugarbaker DJ, Flores RM, Jakiltsch MT, et al.: Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: Results in 183 patients. J Thorac Cardiovasc Surg 1999, 117:54-65. This paper shows the latest result of the largest series of patients treated with trimodality therapy, demonstrating that trimodality therapy is not curative and the median survival in this highly selected group of patients is 19 months.
67. 67 Butchart EG, Ashcroft T, Bamsley WC, Holden M: The role of surgery in diffuse malignant mesothelioma of the pleura. Semin Oncol 1981,8:321-328.
68. 68 Calavrezos A, Koschel G, Husselmann H, et al.: Malignant mesothelioma of the pleura: a prospective therapeutic study of 132 patients from 1981-1985. Kin Wochenschr 1988, 66:607-613.
69. 69 Astoul P, Viallat JR, Laurent JC, Brandely M, Boulin C: Intrapleural recombinant IL-2 in passive immunotherapy for malignant pleural mesothelioma. Chest 1993, 103:209-213.
70. 70 Solomons K: Malignant mesothelioma-clinical and epidemiological features: A report of 80 cases. S Afr Med J 1984, 66:407-412.
71. 71 Pass HI, Robinson BW, Testa JR, Carbone M: Emerging translational therapies for mesothelioma. Chest 1999, 116:455S-460S. This paper provides a very good overview of the latest bench-work investigations for novel therapies for mesothelioma.
72. 72 Costanzi J, Darzynkiewicz Z, Chun H, et al.: The use of Onconase for patients with advanced malignant mesothelioma [abstract]. Philadelphia: IMIG 1997:59.
73. 73 Grondin SC, Sugarbaker DJ: Malignant mesothelioma of the pleural space. Oncology 1999, 13(7):919-926.
74. 74 Lukacs KV, Oakley RE, Pardo OE, et al.: Gene therapy for malignant mesothelioma with a heat shock protein gene [abstract]. Am J Respir Crit Care Med 1998, 157(3):A741.
75. 75 Fitzpatrick DR, Peroni DJ, Bielefeldt-Ohmann H: The role of growth factors and cytokines in the tumorigeneses and immunobiology of malignant mesothelioma. Am J Respir Cell Mol Biol 1995, 12:455-460.
76. 76 Marzo AL, Fitzpatrick DR, Robinson BW, Scott B: Antisense oligonucleotides specific for transforming growth factor beta2 inhibit the growth of malignant mesothelioma both in vitro and in vivo. Cancer Res 1997, 57(15):3200-3207.
77. 77 Glaffy G, Mohammed KA, Narseen N, Ward MJ, Antony VB: Inhibition of interleukin-8 reduces human malignant pleural mesothelioma propagation in nude mouse model. Oncol Res 1999, 11:187-194.
78. 78 Caminschi E, Venetsanakos E, Leong CC, et al.: Interleukin-12 induces an effective antitumor response in malignant mesothelioma. Am J Respir Cell Mol Biol 1998, 19:738-746.
79. 79 Waheed I, Guo ZS, Chen GA, et al.: Antisense to SV40 early gene region induces growth arrest and apoptosis in T-antigen-positive human pleural mesothelioma cells. Cancer Res 1999, 59:6068-6073.
80. 80 Patz EFJ, Shaffer K, Piwnica-Worms DR, et al.: Malignant plerual mesothelioma: value of CT and MRI imaging in predicting resectability. AJR 1992, 159:961-966.
81. 81 Benard F, Sterman DH, Smith RJ, et al.: Metabolic imaging of malignant pleural mesothelioma with fluorine-18-deoxyglucose positron emission tomography. Chest 1998, 114:713-722.
82. 82 Lee YC, Knox BS, Garrett JE: Use of cytokeratin fragments 19.1 and 19.21 (Cyfra 21-1) in the differentiation of malignant and benign pleural effusions. Aust NZ J Med 1999, 29:765-769.
83. 83 Schouwink H, Korse CM, Bonfrer JM, et al.: Prognostic value of the serum tumour markers Cyfra 21-1 and tissue polypeptide antigen in malignant mesothelioma. Lung Cancer 1999, 25:25-32.